Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yan Xue is active.

Publication


Featured researches published by Yan Xue.


BMC Cancer | 2011

NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression

Jin Zheng; Yan Li; Jiandong Yang; Qiang Liu; Ming Shi; Rui Zhang; Hengjun Shi; Qinyou Ren; Ji Ma; Hang Guo; Yurong Tao; Yan Xue; Ning Jiang; Libo Yao; Wenchao Liu

BackgroundThe prognosis of most hepatocellular carcinoma (HCC) patients is poor due to the high metastatic rate of the disease. Understanding the molecular mechanisms underlying HCC metastasis is extremely urgent. The role of CD24 and NDRG2 (N-myc downstream-regulated gene 2), a candidate tumor suppressor gene, has not yet been explored in HCC.MethodsThe mRNA and protein expression of CD24 and NDRG2 was analyzed in MHCC97H, Huh7 and L-02 cells. Changes in cell adhesion, migration and invasion were detected by up- or down-regulating NDRG2 by adenovirus or siRNA. The expression pattern of NDRG2 and CD24 in HCC tissues and the relationship between NDRG2 and HCC clinical features was analyzed by immunohistochemical and western blotting analysis.ResultsNDRG2 expression was negatively correlated with malignancy in HCC. NDRG2 exerted anti-tumor activity by regulating CD24, a molecule that mediates cell-cell interaction, tumor proliferation and adhesion. NDRG2 up-regulation decreased CD24 expression and cell adhesion, migration and invasion. By contrast, NDRG2 down-regulation enhanced CD24 expression and cell adhesion, migration and invasion. Immunohistochemical analysis of 50 human HCC clinical specimens showed a strong correlation between NDRG2 down-regulation and CD24 overexpression (P = 0.04). In addition, increased frequency of NDRG2 down-regulation was observed in patients with elevated AFP serum level (P = 0.006), late TNM stage (P = 0.009), poor differentiation grade (P = 0.002), tumor invasion (P = 0.004) and recurrence (P = 0.024).ConclusionsOur findings indicate that NDRG2 and CD24 regulate HCC adhesion, migration and invasion. The expression level of NDRG2 is closely related to the clinical features of HCC. Thus, NDRG2 plays an important physiological role in HCC metastasis.


BMC Cancer | 2014

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

Ji Ma; Yan Guo; Suning Chen; Cuiping Zhong; Yan Xue; Yuan Zhang; Xiaofeng Lai; Yifang Wei; Shentong Yu; Jian Zhang; Wenchao Liu

BackgroundTamoxifen, an endocrine therapy drug used to treat breast cancer, is designed to interrupt estrogen signaling by blocking the estrogen receptor (ER). However, many ER-positive patients are low reactive or resistant to tamoxifen. Metformin is a widely used anti-diabetic drug with noteworthy anti-cancer effects. We investigated whether metformin has the additive effects with tamoxifen in ER-positive breast cancer therapy.MethodsThe efficacy of metformin alone and in combination with tamoxifen against ER-positive breast cancer was analyzed by cell survival, DNA replication activity, plate colony formation, soft-agar, flow cytometry, immunohistochemistry, and nude mice model assays. The involved signaling pathways were detected by western blot assay.ResultsWhen metformin was combined with tamoxifen, the concentration of tamoxifen required for growth inhibition was substantially reduced. Moreover, metformin enhanced tamoxifen-mediated inhibition of proliferation, DNA replication activity, colony formation, soft-agar colony formation, and induction of apoptosis in ER-positive breast cancer cells. In addition, these tamoxifen-induced effects that were enhanced by metformin may be involved in the bax/bcl-2 apoptotic pathway and the AMPK/mTOR/p70S6 growth pathway. Finally, two-drug combination therapy significantly inhibited tumor growth in vivo.ConclusionThe present work shows that metformin and tamoxifen additively inhibited the growth and augmented the apoptosis of ER-positive breast cancer cells. It provides leads for future research on this drug combination for the treatment of ER-positive breast cancer.


PLOS ONE | 2013

Role of Activated Rac1/Cdc42 in Mediating Endothelial Cell Proliferation and Tumor Angiogenesis in Breast Cancer

Ji Ma; Yan Xue; Wenchao Liu; Caixia Yue; Feng Bi; Junqing Xu; Jian Zhang; Yan Li; Cuiping Zhong; Yan Chen

Angiogenesis is a well-established target in anti-cancer therapy. Although vascular endothelial growth factor (VEGF)-mediated angiogenesis apparently requires the Rho GTPases Rac1 and Cdc42, the relevant mechanisms are unclear. Here, we determined that activated Rac1/Cdc42 in MCF-7 breast cancer cells could decrease p53 protein levels and increase VEGF secretion to promote proliferation and tube formation of human umbilical vein endothelial cells (HUVECs). However, these effects are reversed after ubiquitin-proteasome breakage. In exploring potential mechanisms for this relationship, we confirmed that activated Rac1/Cdc42 could enhance p53 protein ubiquitination and weaken p53 protein stability to increase VEGF expression. Furthermore, in a xenograft model using nude mice that stably express active Rac1/Cdc42 protein, active Rac1/Cdc42 decreased p53 levels and increased VEGF expression. Additionally, tumor angiogenesis was inhibited, and p53 protein levels were augmented, by intratumoral injection of the ubiquitin-proteasome inhibitor MG132. Finally in 339 human breast cancer tissues, our analyses indicated that Rac1/Cdc42 expression was related to advanced TNM staging, high proliferation index, ER status, and positive invasive features. In particular, our data suggests that high Rac1/Cdc42 expression is correlated with low wt-p53 and high VEGF expression. We conclude that activated Rac1/Cdc42 is a vascular regulator of tumor angiogenesis and that it may reduce stability of the p53 protein to promote VEGF expression by enhancing p53 protein ubiquitin.


PLOS ONE | 2012

Inhibition of endothelial cell proliferation and tumor angiogenesis by up-regulating NDRG2 expression in breast cancer cells.

Ji Ma; Wenchao Liu; Xiaohong Yan; Qianrong Wang; Qingli Zhao; Yan Xue; Hui Ren; Lin Wu; Yuanxiong Cheng; Sen Li; Lu Miao; Libo Yao; Jian Zhang

The N-myc downstream-regulated gene 2 (NDRG2) is involved in tumor cell differentiation and apoptosis, but its function in tumor angiogenesis remains to be established. Here, we employed adenovirus overexpressing NDRG2 (Ad-NDRG2) to efficiently up-regulate target gene expression in the NDRG2-low-expressing, breast cancer cell line MCF-7. Moreover, VEGF secretion was decreased in MCF-7 cells infected by Ad-NDRG2, and medium conditioned by these infected cells could significantly inhibit the proliferation, tube formation and invasion of human umbilical vein endothelial cells (HUVECs). Further study indicated that the angiogenesis promoting factors VEGF and HIF-1α were down-regulated, whereas the angiogenesis suppressing factors p53 and VHL were up-regulated in MCF-7 cells infected by Ad-NDRG2. Finally, in a nude mouse model, intratumoral injections of Ad-NDRG2 every 3 days for 20 days significantly inhibited the growth and angiogenesis of xenografted MCF-7 tumors. In summary, these data indicate that NDRG2 may be involved in angiogenesis by impacting the expression of angiogenesis related factors. Thus, specific overexpression of NDRG2 by adenovirus represents a promising approach for the treatment of tumor angiogenesis.


Cancer | 2012

Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions.

Ji Ma; Yan Xue; Wei Cui; Yan Li; Qingli Zhao; Wenmin Ye; Jin Zheng; Yuanxiong Cheng; Yuguang Ma; Sen Li; Tenglong Han; Lu Miao; Libo Yao; Jian Zhang; Wenchao Liu

Tumor neovascularization (TNV) is a common pathologic basis for malignant growth and metastasis. However, the mechanism of TNV pathogenesis is not fully understood. Ras homolog gene family, member A (RhoA), a Rho guanosine triphosphatase (GTPase) family member, may be involved in a hypoxia‐induced vascular endothelial growth factor (VEGF) pathway that regulates TNV angiogenesis through an unclear mechanism.


Medical Oncology | 2012

Adenovirus-mediated RhoA shRNA suppresses growth of esophageal squamous cell carcinoma cells in vitro and in vivo.

Ji Ma; Jian Zhang; Yuguang Ma; Jin Zheng; Yuanxiong Cheng; Yan Xue; Wenchao Liu

Over-expression of RhoA in esophageal squamous cell carcinoma (ESCC) indicates a poor prognosis and is correlated with the tumor-node-metastasis (TNM) clinical classification. However, until now RhoA function in the ESCC progression remains to be established. We employed adenovirus-mediated small hairpin RNA (shRNA) against human RhoA (Ad-sh-RhoA) to efficiently silence target gene expression in RhoA-expressing Eca-109 ESCC cells at both protein and mRNA levels. Consequently, Ad-sh-RhoA reduced the proliferation and migration of Eca-109 cells assayed by MTT assay and cell wound healing, respectively. Moreover, Ad-sh-RhoA increased cell apoptosis and inhibited the cell cycle G1-S-phase progression of Eca-109 cells assessed by flow cytometry. Finally, in a nude mouse model, intratumoral injections of adenovirus-delivered RhoA shRNA every 3xa0days for 20xa0days significantly inhibited the growth and angiogenesis of xenografted Eca-109 tumors. In summary, these data indicate that RhoA may be a key molecule in ESCC cells, and thus, specific inhibition of the Rho signaling pathway with adenovirus-delivered shRNA represents a promising approach for the treatment of aggressive ESCC.


Brazilian Journal of Medical and Biological Research | 2013

AKT inhibitor suppresses hyperthermia-induced Ndrg2 phosphorylation in gastric cancer cells

Yurong Tao; Yan Guo; Wenchao Liu; Jian Zhang; Xia Li; Lan Shen; Yi Ru; Yan Xue; Jin Zheng; Xinping Liu; Jing Zhang; Libo Yao

Hyperthermia is one of the most effective adjuvant treatments for various cancers with few side effects. However, the underlying molecular mechanisms still are not known. N-myc downstream-regulated gene 2 (NDRG2), a tumor suppressor, has been shown to be involved in diverse cellular stresses including hypoxia, lipotoxicity, etc. In addition, Ndrg2 has been reported to be related to progression of gastric cancer. In the current study, our data showed that the apoptosis rate of MKN28 cells increased relatively rapidly to 13.4% by 24 h after treatment with hyperthermia (42°C for 1 h) compared to 5.1% in control cells (P < 0.05). Nevertheless, there was no obvious change in the expression level of total Ndrg2 during this process. Further investigation demonstrated that the relative phosphorylation levels of Ndrg2 at Ser332, Thr348 increased up to 3.2- and 1.9-fold (hyperthermia group vs control group) at 3 h in MKN28 cells, respectively (P < 0.05). We also found that heat treatment significantly increased AKT phosphorylation. AKT inhibitor VIII (10 µM) decreased the phosphorylation level of Ndrg2 induced by hyperthermia. Accordingly, the apoptosis rate rose significantly in MKN28 cells (16.4%) treated with a combination of AKT inhibitor VIII and hyperthermia compared to that (6.8%) of cells treated with hyperthermia alone (P < 0.05). Taken together, these data demonstrated that Ndrg2 phosphorylation could be induced by hyperthermia in an AKT-dependent manner in gastric cancer cells. Furthermore, AKT inhibitor VIII suppressed Ndrg2 phosphorylation and rendered gastric cancer cells susceptible to apoptosis induced by hyperthermia.


Asian Pacific Journal of Cancer Prevention | 2010

NDRG2 Expression Regulates CD24 and Metastatic Potential of Breast Cancer Cells

Jin Zheng; Qiang Liu; Yan Li; Jiandong Yang; Ji Ma; Fang Yu; Hengjun Shi; Qinyou Ren; Rui Zhang; Jin Zhang; Yan Xue; Yurong Tao; Ning Jiang; Hang Guo; Libo Yao; Wenchao Liu


PLOS ONE | 2014

Interaction index (Ix) based on isobologram curve for MCF-7, SKBR3 and MCF-7/HER2 breast cancer cells with cerulenin combined with rapamycin treatment showed the combination treatment could produce synergetic cytotoxicity.

Yan Chen; Wei Huang; Minjuan Zheng; Yan Xue; Jing-Yue Yang; Wenchao Liu; Sheng Han


PLOS ONE | 2014

The transcriptional activities of FASN in SKBR3, MCF-7and MCF-7/HER2 breast cancer cells treated with mTOR inhibitor rapamycin.

Yan Chen; Wei Huang; Minjuan Zheng; Yan Xue; Jing-Yue Yang; Wenchao Liu; Sheng Han

Collaboration


Dive into the Yan Xue's collaboration.

Top Co-Authors

Avatar

Wenchao Liu

Fourth Military Medical University

View shared research outputs
Top Co-Authors

Avatar

Ji Ma

Fourth Military Medical University

View shared research outputs
Top Co-Authors

Avatar

Jian Zhang

Fourth Military Medical University

View shared research outputs
Top Co-Authors

Avatar

Jin Zheng

Fourth Military Medical University

View shared research outputs
Top Co-Authors

Avatar

Libo Yao

Fourth Military Medical University

View shared research outputs
Top Co-Authors

Avatar

Yan Chen

Fourth Military Medical University

View shared research outputs
Top Co-Authors

Avatar

Yan Li

Fourth Military Medical University

View shared research outputs
Top Co-Authors

Avatar

Jing-Yue Yang

Fourth Military Medical University

View shared research outputs
Top Co-Authors

Avatar

Yuanxiong Cheng

Southern Medical University

View shared research outputs
Top Co-Authors

Avatar

Yurong Tao

Fourth Military Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge